Kieran P. Murphy, Former CEO of GE Healthcare, Joins Gamma Biosciences as Executive Chairman
Gamma Biosciences, formed by KKR, has appointed Kieran P. Murphy as Executive Chairman to enhance its leadership in advanced therapy manufacturing. Mr. Murphy, with significant experience from GE Healthcare, will guide Gamma as it develops its technology portfolio for cell and gene therapy, protein biologics, and vaccines. His expertise aims to address challenges in the growing market for next-generation therapies. The appointment is effective March 16, 2022, signaling a strategic move to accelerate Gamma's growth and innovation in the bioprocessing industry.
- Appointment of Kieran P. Murphy as Executive Chairman is expected to accelerate strategic growth.
- Murphy brings extensive experience from leading roles in GE Healthcare, enhancing Gamma's industry leadership.
- Focus on advanced therapy manufacturing positions Gamma favorably in a rapidly growing market.
- None.
“I couldn’t be more pleased to welcome Kieran aboard as we enter the next phase of our journey”, said
“I am delighted to have the opportunity to join the Gamma team and to work closely with Matt and the board. I believe the company is building a portfolio of industry-leading technologies addressing a number of critical challenges in the rapidly growing market for next-generation therapies,” commented
“We are thrilled to have Kieran joining Gamma at this very exciting moment for the company. We have long admired Kieran’s strategic instincts, operating rigor, and entrepreneurial vigor, and believe his long history of leadership, experience, and insights will prove to be tremendously helpful to Gamma,” said Kugan Sathiyanandarajah, Managing Director at KKR and Head of
About Gamma Biosciences
Gamma Biosciences is a leading life sciences company providing products and services to support the development and manufacturing of advanced biologic therapies. We are committed to advancing the science and art of bioprocessing by delivering market-ready innovation and expertise to our customers, mainly biopharmaceutical developers and contract development and manufacturing companies, helping them bring therapies to patients more quickly and efficiently with the highest standards of quality. Gamma is a global company with offices and major manufacturing facilities in
About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005514/en/
Media Contacts
Alastair Elwen /
Finsbury Glover Hering
Telephone: +44 20 7251 3801
Email: KKR-LON@finsbury.com
Source: KKR
FAQ
What is the new position held by Kieran P. Murphy at Gamma Biosciences?
When did Kieran P. Murphy assume his role at Gamma Biosciences?
What experience does Kieran P. Murphy bring to Gamma Biosciences?
How is Gamma Biosciences positioned in the advanced therapy market?